The postthrombotic syndrome (PTS) is a frequent complication of deep venous thrombosis (DVT). Clinically, PTS is characterized by chronic, persistent pain, swelling, and other signs in the affected limb. Rarely, ulcers may develop. Because of its prevalence, severity, and chronicity, PTS is burdensome and costly. Preventing DVT with the use of effective thromboprophylaxis in high-risk patients and settings and minimizing the risk of ipsilateral DVT recurrence are likely to reduce the risk of development of PTS. Daily use of compression stockings after DVT might reduce the incidence and severity of PTS, but consistent and convincing data about their effectiveness are not available. Future research should focus on standardizing diagnostic criteria for PTS, identifying patients at high risk for PTS, and rigorously evaluating the role of thrombolysis in preventing PTS and of compression stockings in preventing and treating PTS. In addition, novel therapies should be sought and evaluated.

The postthrombotic syndrome (PTS) is a chronic condition that develops in 20% to 50% of patients within 1 to 2 years of symptomatic deep venous thrombosis (DVT). A severe form, which can include venous ulcers, occurs in one quarter to one third of patients with PTS.1,2 Because of its prevalence and chronicity, PTS is costly to society and is a cause of substantial patient morbidity.

In this article, we critically review the evidence informing current understanding of the pathophysiology, epidemiology, diagnosis, and management of PTS. The burden of PTS from both a patient and a societal perspective is discussed. Using standard criteria to grade the quality of the available evidence, we provide recommendations for the prevention and treatment of PTS. This article also acknowledges controversies in the field and key areas of ongoing and future research.
lateral vein, is associated with clinical manifestations of PTS. Therefore, preventing valve damage and reducing venous hypertension are likely to be important in preventing PTS.

**Factors That Predict the Development of PTS After DVT**

**Recurrent DVT**

The only clearly identified risk factor for PTS is recurrent, ipsilateral DVT, which increases the risk of PTS as much as 6-fold. Recurrent DVT probably causes additional damage to already compromised venous valves and further venous outflow obstruction.

**Characteristics of the Initial DVT**

There is little correlation between the venographic severity of the initial thrombus and subsequent development of PTS. In some studies, the risk of PTS was higher in patients with proximal rather than distal (calf) DVT, while in others the site of the initial thrombus did not influence the subsequent development of PTS. In prospective studies, reported rates of PTS after distal DVT have ranged from 20% to 80%. Hence, calf DVT is associated with a significant risk of subsequent PTS.

**Asymptomatic DVT**

Whether asymptomatic DVT (ie, detected by routine screening) leads to PTS is controversial. One study found that the frequency of PTS 2 to 7 years after hip or knee arthroplasty was similarly low (approximately 5%) in patients whose routine predischarge venogram showed proximal DVT, calf DVT, or no DVT. All patients with DVT received 6 to 12 weeks of anticoagulant therapy. Other investigators have also found low rates of PTS after asymptomatic DVT. Conversely, some groups have shown that as many as 25% to 33% of patients with asymptomatic DVT develop PTS.

Differences in patient selection, study design, and definition of PTS may explain these discrepant results, but if confirmed, this would support the clinical relevance of asymptomatic DVT in studies of thromboprophylaxis and would provide a rationale for reducing the risk of such thrombi.

**Patient Characteristics**

In prospective studies, clinical features such as delay in initiating treatment for DVT; risk factors for thrombosis; family history of thrombosis; protein C, protein S, or antithrombin deficiency; or the presence of the lupus anticoagulant have not been found to increase the risk of developing PTS. In retrospective studies, factors predictive of PTS were increasing age, female sex, hormone therapy, varicose veins, abdominal surgery, and increased body mass index.

**Diagnosis of PTS**

There is no gold standard test for the diagnosis of PTS. In patients with objectively confirmed DVT and a typical clinical presentation, PTS is usually the correct diagnosis. As it usually takes 3 to 6 months after acute DVT for the initial pain and swelling to resolve, a diagnosis of PTS should be deferred until after this time. Objective evidence of venous valvular incompetence by Doppler ultrasound or by plethysmography helps to confirm the diagnosis in symptomatic patients. However, a diagnosis of PTS should not be made in the absence of clinical symptoms; while most patients with symptomatic PTS have valvular incompetence, many with valvular incompetence do not have PTS.

Three clinical scales for the diagnosis of PTS are available and have been used in a number of clinical studies. They are presented in detail in Table 2.

**Impact of PTS**

**Population-Based Studies: Incidence and Prevalence**

The prevalence of PTS is influenced by the incidence of DVT. Despite advances in its prevention and treatment, the annual incidence of venous thromboembolism (VTE) (ie, DVT and pulmonary embolism) has not decreased and is 1.0 to 1.6 per 1000 persons per year, with a per-person lifetime incidence of 2% to 5%. Approximately 250000 new cases of VTE occur in the United States each year. The population burden of PTS is difficult to estimate because of varying definitions of PTS and a tendency to underestimate chronic conditions. In a recent study, cumulative rates of venous stasis were 7.3% at 1 year, 14.3% at 5 years, 19.7% at 10 years, and 26.8% at 20 years after DVT; the cumulative risk of ulcer was 3.7% by 20 years. It is estimated that more than one quarter of the at least 170000 new cases of venous stasis syndrome per year represent PTS.

**Clinical Studies: Frequency of PTS After DVT**

The frequency of PTS after objectively diagnosed DVT is difficult to estimate. Many studies have used surrogate end points such as reflux or abnormal results of venography without consideration of clinical symptoms and signs, and few have used validated PTS scores.

Nonetheless, a few prospective studies have provided key information on the frequency of PTS after symptomatic DVT. In a longitudinal cohort study of patients with a first episode of acute symptomatic DVT, Prandoni et al found that...
the cumulative incidence of PTS was 17.3% after 1 year (severe in 3%), 23% after 2 years, 28% after 5 years (severe in 9%), and 29% after 8 years. In a subsequent trial to evaluate the use of compression stockings to prevent PTS in patients with symptomatic proximal DVT, mild to moderate PTS occurred in 20% of patients assigned to stockings and in 47% of controls, and severe PTS occurred in 11% and 23%, respectively.2 The frequency of PTS in the stockings group was similar to that in the study by Prandoni et al, in which all patients were encouraged to wear compression stockings. In both studies, most cases of PTS occurred within 2 years of DVT. In contrast, in a recent study by Ginsberg and colleagues,33 27% of patients (none of whom used stockings) had developed PTS by 1 year after a first episode of symptomatic proximal DVT, but among patients who were free of PTS 1 year after DVT, only 5% subsequently developed PTS (average follow-up, 55 months). However, the Ginsberg et al study used stricter diagnostic criteria for PTS: in addition to symptoms, objective demonstration of valvular incompetence was required.

In summary, the frequency of PTS after symptomatic DVT ranges from 15% to 50%. In most cases, PTS develops within 1 to 2 years after DVT. Severe PTS occurs in 5% to 10% of patients after DVT.

Table 2. Clinical Scales for the Diagnosis of Postthrombotic Syndrome

<table>
<thead>
<tr>
<th>PTS Scale</th>
<th>Criteria Used to Diagnose PTS</th>
<th>Test Characteristics</th>
<th>Developed Specifically for PTS</th>
<th>Rates Severity of PTS</th>
</tr>
</thead>
</table>
| Ginsberg et al32 | Pain and swelling of limb of ≥1-mo duration, typical character (worse at end of day or with prolonged sitting/standing, better after night’s rest and leg elevation) that occurs ≥6 mo after acute DVT and Objective evidence of valvular incompetence (diagnosed via plethysmography or venous Doppler)  
- If both criteria are present, PTS is diagnosed  
- Global Rating Questionnaire to rate overall improvement or worsening of PTS over time | Not assessed          | Yes               | No                   |
| Villalta et al35 | 5. Symptoms (pain, cramps, heaviness, pruritus, paresthesia)  
6. Signs (edema, skin induration, hyperpigmentation, venous ectasia, redness, pain during calf compression)  
Each rated as 0 (absent), 1 (mild), 2 (moderate), or 3 (severe) Points are summed  
Total score:  
0-4: No PTS  
5-14: Mild/moderate PTS  
≥15, or presence of ulcer: Severe PTS | Interobserver agreement:  
κ = 0.80 for symptoms,  
0.77 for signs, 0.75 for total score | Yes               | Yes               |
| CEAP classification44,46+ | Patients with chronic venous disease classified into 1 of 7 clinical classes (class 0-6) according to presence of clinical signs; each class may include signs present in lower-order class  
Class:  
0. Symptoms only; no visible or palpable signs of venous disease  
1. Telangiectasias, reticular veins, malleolar flare  
2. Varicose veins  
3. Edema, no skin changes  
4. Skin changes (eg, pigmentation, eczema, lipodermatosclerosis)  
5. Skin changes with healed ulcer  
6. Skin changes with active ulcer  
Each clinical class is then subclassified as to:  
Etiology (congenital, primary, secondary)  
Anatomy (superficial, deep, perforator veins)  
Pathophysiology (reflux, obstruction, both) | Not assessed          | No† | No‡ |

Abbreviations: CEAP, Clinical-Etiology-Anatomic-Pathophysiologic; DVT, deep venous thrombosis; PTS, postthrombotic syndrome; ROC, receiver operating characteristic.

*Modifications of CEAP (Clinical Severity Score, Venous Segmental Disease Score) have been proposed.46
†Developed for chronic venous disease in general.
‡Increasing CEAP class is intended to reflect increased severity of signs of chronic venous disease; symptoms and their severity are not considered.

Cost of PTS

Although there is little direct-cost information available, PTS undoubtedly incurs high direct costs and indirect costs such as loss of productivity. A Swedish study estimated that the average cost of treating PTS was US $4700, or 75% of the cost of treating the primary DVT.38 Extrapolations can be made from the
Table 3. Prospective Studies of the Frequency of Postthrombotic Syndrome After Symptomatic DVT

<table>
<thead>
<tr>
<th>Source</th>
<th>DVT Type</th>
<th>No. *</th>
<th>Duration of Follow-up, y</th>
<th>% Regular Stocking Use</th>
<th>Definition of PTS</th>
<th>Frequency of PTS, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stramandin et al,23 1983</td>
<td>Any</td>
<td>65 Limbs</td>
<td>3 (Mean)</td>
<td>74</td>
<td>Pain, edema, skin changes, ulcer</td>
<td>67</td>
</tr>
<tr>
<td>Kakkar and Lawrence,55 1985</td>
<td>Any</td>
<td>97 Limbs</td>
<td>2 (Total)</td>
<td>NR</td>
<td>10-Point scoring system based on symptoms and signs</td>
<td>84</td>
</tr>
<tr>
<td>Monreal et al,21 1993</td>
<td>First episode</td>
<td>84 Limbs</td>
<td>3 (Total)</td>
<td>NR</td>
<td>10-Point scoring system based on symptoms and signs</td>
<td>56</td>
</tr>
<tr>
<td>Johnson et al,14 1995</td>
<td>First episode</td>
<td>83 Limbs</td>
<td>3 (Median)</td>
<td>47</td>
<td>Edema, skin changes, ulcer</td>
<td>41</td>
</tr>
<tr>
<td>Prandoni et al,1 1996</td>
<td>First episode</td>
<td>355</td>
<td>8 (Total)</td>
<td>100</td>
<td>Villalta et al scale</td>
<td>29</td>
</tr>
<tr>
<td>Brandjes et al,1997 proximal</td>
<td>194</td>
<td>6 (Median)</td>
<td>100 (n = 96)/0 (n = 98)</td>
<td>Villalta et al scale</td>
<td>31/70</td>
<td></td>
</tr>
<tr>
<td>Franzek et al,10 1997</td>
<td>Any 39</td>
<td></td>
<td>12 (Mean)</td>
<td>54</td>
<td>CEAP scale</td>
<td>36</td>
</tr>
<tr>
<td>AbuRahma et al,98 1998</td>
<td>First episode proximal</td>
<td>87</td>
<td>5 (Mean)</td>
<td>NR</td>
<td>Edema, skin changes, ulcer</td>
<td>36</td>
</tr>
<tr>
<td>Masuda et al,27 1998</td>
<td>Distal</td>
<td>23</td>
<td>3 (Median)</td>
<td>NR</td>
<td>CEAP scale</td>
<td>57</td>
</tr>
<tr>
<td>Meissner et al,98 1998</td>
<td>First episode</td>
<td>73 Limbs</td>
<td>4½ (Mean)</td>
<td>NR</td>
<td>CEAP scale</td>
<td>73</td>
</tr>
<tr>
<td>Saarinen et al,30 2000</td>
<td>Any 28</td>
<td></td>
<td>2 (Total)</td>
<td>12</td>
<td>Pain, edema, skin changes, ulcer</td>
<td>73</td>
</tr>
<tr>
<td>Ginsberg et al,1 2001</td>
<td>First episode proximal</td>
<td>110</td>
<td>1</td>
<td>0</td>
<td>Chronic persistent leg pain and swelling and valvular incompetence</td>
<td>27</td>
</tr>
<tr>
<td>Haenen et al,23 2001</td>
<td>Any 79 Limbs</td>
<td></td>
<td>2 (Total)</td>
<td>NR</td>
<td>CEAP scale</td>
<td>77</td>
</tr>
</tbody>
</table>

Abbreviations: CEAP, Clinical-Etiology-Anatomic-Pathophysiologic; DVT, deep venous thrombosis; NR, not reported; PTS, postthrombotic syndrome.

*Number of patients unless otherwise specified.
†Severe PTS includes ulcers, when frequency of ulcers was reported.
‡Randomized trial of stockings vs no stockings after DVT; data presented by treatment group (stockings/no stockings).

Impact of PTS on Quality of Life

For chronic conditions such as PTS, assessment of quality of life can provide important information on burden of illness.3,6,7 In a recent Canadian study, patients with venous ulcers composed 6% of home care clientele but consumed 18% of supply expenditures, and the annual cost of their care was more than $1 million.62 The direct cost of treating chronic venous insufficiency exceeds $300 million per year in the United States,22 with similar costs in Britain, Belgium, France, Germany, Italy, and Spain.4,6,3,6,4 The indirect costs of PTS are also likely to be significant, since PTS often affects persons of working age. It is estimated that, for leg ulcers, 2 million workdays are lost annually in the United States.66

Costs of treating chronic venous insufficiency and venous ulcers, since a proportion of these cases represent PTS,23,3,6,41 In a recent Canadian study, patients with venous ulcers composed 6% of home care clientele but consumed 18% of supply expenditures, and the annual cost of their care was more than $1 million.62 The direct cost of treating chronic venous insufficiency exceeds $300 million per year in the United States,22 with similar costs in Britain, Belgium, France, Germany, Italy, and Spain.4,6,3,6,4 The indirect costs of PTS are also likely to be significant, since PTS often affects persons of working age. It is estimated that, for leg ulcers, 2 million workdays are lost annually in the United States.66

\[ \text{Frequency of PTS, %} \]

<table>
<thead>
<tr>
<th>Stocking Use</th>
<th>Definition of PTS</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain, edema, skin changes, ulcer</td>
<td>10-Point scoring system based on symptoms and signs</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>Edema, skin changes, ulcer</td>
<td>Villalta et al scale</td>
<td>29</td>
<td></td>
</tr>
</tbody>
</table>

The authors mention that nearly 90% of patients were disabled and unable to work because of leg symptoms 10 or more years after iliofemoral DVT.70 In a study of patients who had DVT 6 to 8 years earlier, those with PTS had poorer health perceptions, worse physical functioning, and more severe role limitations, as measured by the SF-36 Health Survey quality-of-life questionnaire.73 Recently, in the course of conducting the Venous Insufficiency Epidemiologic and Economic Study (VEINES), our group developed and validated the VEINES-QOL/Sym questionnaire, a venous disease-specific quality-of-life measure,71 and showed that by 2 years after DVT, patients with PTS had significantly worse quality of life than those without PTS, and scores worsened with increasing severity of PTS.72

MANAGEMENT OF PTS

Preventing PTS

Thromboprophylaxis. Postthrombotic syndrome can be averted with the use of thromboprophylaxis to prevent DVT in high-risk patients and settings, as recommended in regularly updated consensus guidelines.73 However, audits consistently demonstrate that thromboprophylaxis is underused.74-77 Furthermore, existing thromboprophylaxis regimens do not eliminate the risk of VTE.73 New antithrombotic drugs may be more effective than existing regimens in preventing VTE in high-risk patients.75-84 Since the publication of the last consensus guidelines in 2001,76 newer classes of drugs such as synthetic pentasaccharides have demonstrated promising results in phase 3 trials of VTE prevention when compared with conventional heparins.70,82 Unfortunately, nearly 50% of VTE events occur unpredictably and therefore cannot be prevented with thromboprophylaxis.74,83 Hence, strategies that focus on preventing the development of PTS after DVT are more feasible and more likely to be effective in reducing the burden of PTS than are attempts to prevent the index DVT. Since ipsilateral DVT recurrence is a risk factor for PTS, preventing recurrent DVT by optimizing the intensity and duration of anticoagulation for an initial DVT, taking into account the patient’s risk of recurrence and of bleeding,86-88 is an important goal.

Role of Thrombolysis. The use of thrombolytic therapy in addition to heparin for the treatment of acute DVT leads to higher rates of vein patency and better preservation of valve function than does the use of hepa-
rin alone. However, there is no definitive evidence that thrombolysis leads to lower rates of PTS compared with the use of heparin and warfarin alone.\(^9\) (Table 5)\(^,20,90-95\) Furthermore, thrombolytic trials or registries of treated patients have tended to ignore long-term outcomes such as PTS.\(^89,96-98\) Large controlled trials of standard anticoagulation vs catheter-directed thrombolysis, which may be safer and more effective than systemic therapy,\(^97\) are required to definitively address this issue.

### Elastic Compression Stockings

Graduated elastic compression stockings (ECSs) assist the calf muscle pump, reduce venous hypertension and reflux, and thereby reduce edema and improve tissue microcirculation.\(^99-103\) Knee-length and thigh-length ECSs have equal physiologic effects, but the former are easier to apply and more comfortable.\(^104\)

Notwithstanding their physiologic effects, data on the clinical effectiveness of ECSs in preventing PTS are scarce and inconclusive. Evidence supporting their effectiveness comes primarily from the trial by Brandjes et al\(^2\) of 194 patients with symptomatic proximal DVT. Patients were randomly allocated to daily use of 30- to 40-mm Hg knee-length ECSs for at least 2 years, or no stocking. Use of ECSs resulted in a decrease from 47% to 20% of mild or moderate PTS, and from 23% to 11% of severe PTS, diagnosed with the scale of Villalta et al\(^15\) (see Table 2). As a result of this trial, it has become common clinical practice to prescribe ECSs for patients with DVT, particularly proximal DVT.\(^105\) However, a recent randomized trial conducted by Ginsberg and colleagues\(^33\) showed no benefit of daily ECSs in preventing or treating PTS. This study used a more specific measure of PTS than that of Brandjes et al\(^2\) (see Table 2), and control patients wore sham stockings. Because of the small number of patients with PTS, benefit (or harm) of up to 30% compared with the control group could not be excluded.

### Table 4. Prospective Studies of the Frequency of Postthrombotic Syndrome in Patients Screened for Asymptomatic DVT

<table>
<thead>
<tr>
<th>Source</th>
<th>Patient Population</th>
<th>DVT Detection</th>
<th>DVT Treatment</th>
<th>Duration of Follow-up</th>
<th>% Regular Stocking Use</th>
<th>Definition of PTS</th>
<th>No.</th>
<th>Frequency of PTS, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mudge et al,(^57) 1988</td>
<td>Elective major abdominal surgery</td>
<td>FUS</td>
<td>NR</td>
<td>10 (Total)</td>
<td>NR</td>
<td>Any 3 of varicose veins, edema, pigmentation, ulcers</td>
<td>26 DVT (limbs)</td>
<td>8</td>
</tr>
<tr>
<td>Francis et al,(^96) 1988</td>
<td>THA or TKA</td>
<td>CV</td>
<td>3-6 mo A/C</td>
<td>4 (Mean)</td>
<td>NR</td>
<td>Symptoms (swelling, pain, varicosities, ulcers) or signs (edema, ulcer, pigmentation, varicose veins)</td>
<td>19 DVT (limbs)</td>
<td>58</td>
</tr>
<tr>
<td>Andersen and Wille-Jørgensen,(^23) 1991</td>
<td>Surgery (unspecified)</td>
<td>FUS, TS</td>
<td>3-6 mo A/C</td>
<td>5 (Median)</td>
<td>0 (No DVT)</td>
<td>Symptoms and signs</td>
<td>29 DVT (limbs)</td>
<td>38 (Edema)</td>
</tr>
<tr>
<td>McNally et al,(^31) 1994</td>
<td>THA</td>
<td>CV</td>
<td>≥3 mo A/C</td>
<td>5 (Total)</td>
<td>NR</td>
<td>Scoring system based on symptoms and signs</td>
<td>8 DVT (limbs)</td>
<td>88</td>
</tr>
<tr>
<td>Warwick et al,(^14) 1996</td>
<td>THA</td>
<td>FUS, CV</td>
<td>Yes (duration NR)</td>
<td>16 (Mean)</td>
<td>NR</td>
<td>Scoring system based on symptoms and signs</td>
<td>98 DVT (limbs)</td>
<td>47</td>
</tr>
<tr>
<td>Siragusa et al,(^35) 1997</td>
<td>THA or TKA</td>
<td>CV</td>
<td>3 mo A/C</td>
<td>3 (Mean)</td>
<td>NR</td>
<td>Villalta et al scale(^4) and valvar incompetence</td>
<td>46 DVT (limbs)</td>
<td>24</td>
</tr>
<tr>
<td>Ginsberg et al,(^32) 2000</td>
<td>THA or TKA</td>
<td>CV</td>
<td>1.5-3 mo A/C</td>
<td>5 (Mean)</td>
<td>NR</td>
<td>Chronic persistent leg pain and swelling and valvar incompetence</td>
<td>91 DVT (limbs)</td>
<td>5</td>
</tr>
<tr>
<td>Ginsberg et al,(^33) 2001</td>
<td>Major orthopedic surgery</td>
<td>CV</td>
<td>NR</td>
<td>1 (Total)</td>
<td>NR</td>
<td>Chronic persistent leg pain and swelling and valvar incompetence</td>
<td>82 DVT (limbs)</td>
<td>4</td>
</tr>
</tbody>
</table>

Abbreviations: A/C, anticoagulant therapy; CV, contrast venography; DVT, deep venous thrombosis; FUS, fibrinogen I 125 uptake scan; NR, not reported; PTS, postthrombotic syndrome; THA, total hip arthroplasty; TKA, total knee arthroplasty; TS, technetium Tc 99m fibrinolysin scintigraphy.

*Number of patients, unless otherwise specified.
†Severe PTS includes ulcers, when frequency of ulcers was reported.
These results, while not definitive, question the generalizability of the results of the Brandjes et al study, which had unusually high rates of PTS in the control group and dramatic reductions in both relative and absolute risk of PTS in the stocking group.

Stockings are difficult to apply, uncomfortable, and expensive, and require replacement every few months. Because of the uncertainty regarding their value in preventing PTS after DVT, further research on their effectiveness is required.

**Treating PTS**

Available treatments for established PTS are limited. Regular use of ECSs may improve symptoms and swelling. Severe intractable PTS can be managed with long-term use of an intermittent compression extremity pump. Postthrombotic venous ulcers are managed with compression therapy, leg elevation, topical dressings, and sometimes surgery. Ulcers are often recalcitrant and tend to recur, causing pain and suffering to patients and incurring high costs to society. The short-term use of “venoactive” medications such as horse chestnut seed extract or hydroxyethyl rutosides appears to be effective in reducing symptoms of chronic venous insufficiency, however, their long-term effectiveness and safety and their value in patients with PTS are unknown. There is no proven role for the long-term use of diuretics to treat PTS-related edema.

**RECOMMENDATIONS REGARDING PREVENTION AND TREATMENT OF PTS**

The following recommendations for the prevention and treatment of PTS are based on our review of the literature. Levels of evidence, using an adaptation of the categories proposed by Guyatt et al in the sixth American College of Chest Physicians consensus conference on antithrombotic therapy, are used when appropriate.
General Recommendations

- Physicians should actively screen patients with DVT for PTS during follow-up.

The diagnosis of PTS should primarily be based on the presence of typical symptoms and signs, since objective evidence of venous valvular incompetence has low specificity for PTS. However, the presence of valvular incompetence helps to confirm the diagnosis of PTS (and rule out other conditions) in symptomatic patients.

Prevention of PTS

- Prevention of the index DVT will prevent PTS.
- Prevention of ipsilateral DVT recurrence is likely to decrease the risk of developing PTS and prevent worsening of PTS (grade 1C).
- In patients with proximal DVT, the risk of developing PTS may be reduced with daily use of knee-length, 30– to 40–mm Hg ECSs (grade 2B).
- The effects of ECSs after distal DVT and the optimal duration of ECS use are not known.
- There is no convincing evidence that systemic thrombolysis prevents PTS (grades 2B and 2C). Catheter-directed thrombolysis requires further evaluation in properly designed trials before it is endorsed as being effective in reducing the risk of PTS.

Treatment of PTS

- Compression stockings may reduce swelling in some patients with PTS and should be tried. Their benefit in this setting is extrapolated from studies of patients with chronic venous disease but has not been definitively shown in the setting of PTS.
- Severe, intractable PTS can be improved with long-term use of an intermittent compression extremity pump (grade 1A).
- There is no proven role for venoactive medications or diuretics in the management of PTS.

FUTURE DIRECTIONS

Further work needs to be done to increase our understanding of PTS and to test potentially effective preventive and therapeutic interventions. The frequency of PTS in different DVT patient populations (asymptomatic vs symptomatic, proximal vs distal, thrombophilia) should be evaluated in prospective studies of consecutive patients, using a systematic approach to PTS diagnosis. Enumeration of the direct and indirect costs of PTS, identification of key factors that influence costs, and quantification of the impact of PTS on quality of life will allow better estimation of its population burden and more accurate evaluation of the cost-effectiveness of various preventive and therapeutic regimens. Large-scale controlled trials are needed to evaluate the effectiveness, optimal timing, strength, and duration of use of compression stockings in preventing and treating PTS. Multi-center trials of catheter-directed thrombolysis to prevent PTS in patients with extensive proximal DVT are also required. Finally, the value of venoactive agents, diuretics, and anti-inflammatory medications should be studied.

THE VENOUS THROMBOSIS OUTCOMES STUDY

The Venous Thrombosis Outcomes Study is an ongoing Canadian multicenter prospective cohort study being conducted by our group. Its objectives are to estimate the incidence and timing of PTS within 2 years after objectively confirmed DVT and to identify clinical and genetic risk factors that predict its development. Quality of life is being evaluated with the VEINES-QOL/Sym questionnaire, and direct and indirect costs of PTS are being quantified by means of data obtained from multiple sources (patient diaries, patient interviews, hospital chart, health insurance databases). This study will help to enumerate the patient and societal burden of PTS and will identify key variables that most influence quality of life and costs.

SUMMARY

Because of its prevalence, severity, and chronicity, PTS is costly and burdensome to patients and society. It is likely to become more prevalent, since the incidence of DVT has not decreased. The availability of newer, more effective antithrombotic agents may lead to a reduction in the future incidence of DVT, and thereby PTS, in certain settings. The overall frequency of PTS after symptomatic DVT ranges from 20% to 50%; severe PTS occurs in 5% to 10% of patients with DVT. Preventing ipsilateral DVT recurrence is likely to reduce the risk of PTS. There is no proven role for thrombolysis in preventing PTS. Daily use of graduated compression stockings after DVT may reduce the risk of PTS and may prevent the worsening of established PTS. Prevention of PTS is the key to reducing its morbidity, since, at present, treatment options for PTS are extremely limited.

Accepted for publication January 24, 2003.
This work was supported in part by an unrestricted educational grant from Organon-Sanofi Synthelabo. Dr Kahn is a recipient of a Clinical Research Scientist Award from the Fonds de la Recherche en Santé du Québec, Montreal. Dr Ginsberg is a recipient of a Career Investigator Award from the Heart and Stroke Foundation of Ontario, Toronto, and a Research Chair from the Canadian Institutes of Health Research/AstraZeneca, Ottawa, Ontario.

We thank Joan Sobel, PhD, for her help with development of the tables.

Corresponding author: Susan R. Kahn MD, MSc, FRCP(C), Department of Medicine, McGill University, Center for Clinical Epidemiology & Community Studies, Sir Mortimer B. Davis Jewish General Hospital, 3755 Cote Ste Catherine, Room A-127, Montreal, Quebec, Canada H3T 1E2 (e-mail: susan.kahn@mcgill.ca).

REFERENCES

25. Rutherford RB, Padberg FT Jr, Comerota AJ, Kist-


